ClinicalTrials.gg
RecruitingNCT06479122Updated Jun 4, 2025

Efficacy of Acetaminophen Alone Versus Combination of Acetaminophen/Ibuprofen After Cesarean Section

A Phase 4 interventional study of Acetaminophen and Acetaminophen/Ibuprofen in Cesarean Section and Postoperative Pain, sponsored by Seoul National University Hospital. Recruiting at 1 site in Korea, Republic of. Open to female participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-04.

Sponsored by Seoul National University Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
19 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 118 studies testing acetaminophen in Pain, Postoperative — 11 open to participants now, 13 under way, 1 of them phase 3. Acetaminophen · Pain, Postoperative.

Planned enrollment
67th of 118
84 · median 90
Started
2024
with 3 others
Phase 4
53 of 118
9 open now
Primary completion
2026-06
later than 3 of 12 live
Registered
106th of 118
by date
Lead sponsor
4 of 118
Seoul National University Hospital

Among the 118 studies testing acetaminophen in Pain, Postoperative, this one is the 67th largest by planned enrollment, is one of 4 that started in 2024, is one of 53 in phase 4, reaches primary completion later than 3 of the 12 other live ones, and was the 106th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

11 of the 118 studies testing acetaminophen in Pain, Postoperative are open now, in 4 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 19 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies testing acetaminophen in Pain, Postoperative, or all of them as a file.
02

Study summary

The investigators aim to compare the analgesic efficacy of intravenous acetaminophen alone versus combination of acetaminophen/ibuprofen (Maxigesic®IV) in multimodal analgesia after cesarean section.

03

Conditions studied

  • Cesarean Section
  • Postoperative Pain

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients scheduled for elective cesarean section
  • Gestational age > 37+0 weeks

Exclusion criteria

Exclusion Criteria:

  • Emergency cesarean section
  • Multiple pregnancy (e.g. twins, triplets)
  • Body weight \< 50 kg
  • Preeclampsia
  • History of to acetaminophen or ibuprofen
  • History of upper gastrointestinal tract bleeding or gastric ulcer
  • Underlying liver disease
  • Underlying kidney disease or \< 90 mL/min/1.73m2
  • Heart failure or severe hypertension
  • History of asthma
  • Chronic use of barbital or tricyclic antidepressants
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
84 participants (estimated)

Study arms

  • Active comparator
    Acetaminophen

    Drug: Acetaminophen

  • Experimental
    Acetaminophen/Ibuprofen

    Drug: Acetaminophen/Ibuprofen

Interventions

  • 1g acetaminophen is administered during skin closure (end of operation).

    Also known as: Acetaminophen #1

  • DrugAcetaminophen/Ibuprofen

    Drug pages: AcetaminophenStudies of AcetaminophenAcetaminophen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · IbuprofenStudies of IbuprofenIbuprofen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A mixture of 1g acetaminophen and 300 mg ibuprofen (Maxigesic®IV) is administered during skin closure (end of operation)

    Also known as: Acetaminophen/Ibuprofen #1

  • 1g acetaminophen is administered 6 hours after the first administration.

    Also known as: Acetaminophen #2

  • DrugAcetaminophen/Ibuprofen

    Drug pages: AcetaminophenStudies of AcetaminophenAcetaminophen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · IbuprofenStudies of IbuprofenIbuprofen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A mixture of 1g acetaminophen and 300 mg ibuprofen (Maxigesic®IV) is administered 6 hours after the first administration.

    Also known as: Acetaminophen/Ibuprofen #2

06

What researchers measure

Primary outcomes

  1. Obstetric QoR-11K score 24 hours after end of surgery

    Minimum 0, poor recovery; maximum 110, good recovery

    Time frame: 24 hours after end of surgery

Secondary outcomes

  1. Numeric rating scale pain score (0-10) 4 hours after end of surgery

    0, no pain; 10, worst pain imaginable

    Time frame: 4 hours after end of surgery

  2. Numeric rating scale pain score (0-10) 8 hours after end of surgery

    0, no pain; 10, worst pain imaginable

    Time frame: 8 hours after end of surgery

  3. Numeric rating scale pain score (0-10) 12 hours after end of surgery

    0, no pain; 10, worst pain imaginable

    Time frame: 12 hours after end of surgery

  4. Numeric rating scale pain score (0-10) 24 h after end of surgery

    Time frame: 24 h after end of surgery

  5. Numeric rating scale pain score (0-10) 48 hours after end of surgery

    0, no pain; 10, worst pain imaginable

    Time frame: 48 hours after end of surgery

  6. Use of patient-controlled analgesia (FTN, micrograms) during the first 24 hours after end of surgery

    Time frame: 24 h after end of surgery

  7. Use of patient-controlled analgesia (FTN, micrograms) during the first 48 hours after end of surgery

    Time frame: 48 h after end of surgery

  8. Use of rescue analgesia during the first 24 hours after end of surgery

    Time frame: 24 h after end of surgery

  9. Use of rescue analgesia during the first 48 hours after end of surgery

    Time frame: 48 h after end of surgery

  10. Wound-related complications during hospital stay, up to 5 days

    Time frame: From end of surgery to patient discharge, up to 5 days

  11. Operation time

    Time frame: Duration of operation

  12. Anesthesia time

    Time frame: Duration of anesthesia

  13. Injection level of intrathecal drug

    Time frame: After arrival at the operating room

  14. Dosage of intrathecal drug (mg, bupivacaine)

    Time frame: After arrival at the operating room

  15. Sensory blockade level by time point

    Time frame: 0, 5, 10 minutes after intrathecal injection and at the end of operation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Jun 2026, 20 months after the start.

Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 20 months is above that.

Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2024
First posted
Jun 28, 2024
StartActual
Oct 9, 2024
Primary completionEst.
Jun 25, 2026
CompletionEst.
Aug 25, 2026
Last update
Jun 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06479122
Responsible party
Jeong-Hwa Seo (Professor, Seoul National University Hospital) — Principal investigator
First posted
Jun 28, 2024
Start date
Oct 9, 2024
Primary completion
Jun 25, 2026 (estimated)
Completion
Aug 25, 2026 (estimated)
Last update
Jun 4, 2025

Study contacts

Hansol Kim, MD
Contact
hansolfrkr@gmail.com
+82-10-3160-1548
Junghwa Seo, MD, PhD
Contact

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acetaminophen · Ibuprofen

Start the discussion